Press release
Advanced Ovarian Cancer Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim
"Advanced Ovarian Cancer Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Ovarian Cancer Market.
The Advanced Ovarian Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Advanced Ovarian Cancer Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Advanced Ovarian Cancer treatment therapies with a considerable amount of success over the years.
*
Advanced Ovarian Cancer companies working in the treatment market are Daiichi Sankyo, Inc, Amgen, Compugen Ltd, NextCure, Sonnet BioTherapeutics, SOTIO Biotech B.V., Akeso, Allarity Therapeutics, Merck Sharp & Dohme, CanariaBio Inc., Allarity Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., and others, are developing therapies for the Advanced Ovarian Cancer treatment
*
Emerging Advanced Ovarian Cancer therapies in the different phases of clinical trials are- DS-6000a, AMG-794, COM701, NC762, SON-1010, SOT101, AK112, 2X-121, Pembrolizumab, Oregovomab, Stenoparib, DP-303c, and others are expected to have a significant impact on the Advanced Ovarian Cancer market in the coming years.
*
In August 2025, According to a release from Allarity Therapeutics, the U.S. FDA has granted Fast Track designation to stenoparib, an investigational therapy for advanced ovarian cancer. This designation is intended to accelerate the development and review of therapies addressing serious conditions with unmet medical needs. It also enables increased FDA engagement and may provide eligibility for accelerated approval, priority review, or rolling submissions, if specific criteria are satisfied.
*
In November 2024, IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company advancing its DNA-mediated immunotherapy, has announced new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, an investigational interleukin-12 (IL-12) immunotherapy for advanced ovarian cancer developed using its proprietary TheraPlas Registered technology. The findings will be showcased in a late-breaking poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
*
In August 2024, South Korean biopharmaceutical firm CanariaBio completed subject enrollment for its Phase II clinical trial evaluating oregovomab in combination with chemotherapy for advanced epithelial ovarian cancer. Known as FLORA-6, this double-blinded, placebo-controlled, multicenter study aims to assess the effectiveness of oregovomab alongside chemotherapy agents paclitaxel and carboplatin as a neo-adjuvant treatment for newly diagnosed patients.
*
In October 2024, Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company advancing a pipeline of innovative multifunctional biotherapeutics for challenging diseases, has announced the dosing of the first patient in its first-in-human Phase 1 trial (NCT06523803). This study aims to assess the safety and tolerability of the investigational therapy ZW171 for the treatment of advanced or metastatic ovarian cancer, non-small cell lung cancer (NSCLC), and other MSLN-expressing cancers
*
In May 2024, EVT801, a highly selective small-molecule VEGFR3 TKI, demonstrated good tolerability in patients with advanced solid tumors, with a 46% stable disease rate observed in advanced ovarian cancer patients, as reported in a Phase 1 trial (NCT05114668).
Advanced Ovarian Cancer Overview
When it comes to women with gynecological cancer diagnoses, ovarian cancer is the most common cause of death. In general, it ranks as the fifth most common cause of mortality for women. Poor outcomes from this disease are caused by the majority of cases being discovered at an advanced stage.
Get a Free Sample PDF Report to know more about Advanced Ovarian Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/advanced-ovarian-cancer-pipeline-insight [https://www.delveinsight.com/report-store/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Advanced Ovarian Cancer Drugs Under Different Phases of Clinical Development Include:
*
DS-6000a: Daiichi Sankyo, Inc
*
AMG-794: Amgen
*
COM701: Compugen Ltd
*
NC762: NextCure
*
SON-1010: Sonnet BioTherapeutics
*
SOT101: SOTIO Biotech B.V.
*
AK112: Akeso
*
2X-121: Allarity Therapeutics
*
Pembrolizumab: Merck Sharp & Dohme
*
Oregovomab: CanariaBio Inc.
*
Stenoparib: Allarity Therapeutics
*
DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Ovarian Cancer Route of Administration
Advanced Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical.
Advanced Ovarian Cancer Molecule Type
Advanced Ovarian Cancer Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Advanced Ovarian Cancer Pipeline Therapeutics Assessment
*
Advanced Ovarian Cancer Assessment by Product Type
*
Advanced Ovarian Cancer By Stage and Product Type
*
Advanced Ovarian Cancer Assessment by Route of Administration
*
Advanced Ovarian Cancer By Stage and Route of Administration
*
Advanced Ovarian Cancer Assessment by Molecule Type
*
Advanced Ovarian Cancer by Stage and Molecule Type
DelveInsight's Advanced Ovarian Cancer Report covers around 50+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Advanced Ovarian Cancer product details are provided in the report. Download the Advanced Ovarian Cancer pipeline report to learn more about the emerging Advanced Ovarian Cancer therapies [https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Advanced Ovarian Cancer Therapeutics Market include:
Key companies developing therapies for Advanced Ovarian Cancer are - Pfizer, Daiichi Sankyo, Inc., Astellas Pharma Inc, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, ImmunoGen, OncoQuest, Lee's Pharmaceutical, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Bayer, Xennials Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Puma Biotechnology, Inc., MaxCyte, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and others.
Advanced Ovarian Cancer Pipeline Analysis:
The Advanced Ovarian Cancer pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Ovarian Cancer with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Ovarian Cancer Treatment.
*
Advanced Ovarian Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Advanced Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Ovarian Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Advanced Ovarian Cancer drugs and therapies [https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Advanced Ovarian Cancer Pipeline Market Drivers
*
Increasing prevalence of Advanced Ovarian Cancer, increasing research and development activities, launch of novel drugs are some of the important factors that are fueling the Advanced Ovarian Cancer Market.
Advanced Ovarian Cancer Pipeline Market Barriers
*
However, huge expenditure of the treatment methods, adverse effects associated with the drugs and other factors are creating obstacles in the Advanced Ovarian Cancer Market growth.
Scope of Advanced Ovarian Cancer Pipeline Drug Insight
*
Coverage: Global
*
Key Advanced Ovarian Cancer Companies: Daiichi Sankyo, Inc, Amgen, Compugen Ltd, NextCure, Sonnet BioTherapeutics, SOTIO Biotech B.V., Akeso, Allarity Therapeutics, Merck Sharp & Dohme, CanariaBio Inc., Allarity Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., and others
*
Key Advanced Ovarian Cancer Therapies: DS-6000a, AMG-794, COM701, NC762, SON-1010, SOT101, AK112, 2X-121, Pembrolizumab, Oregovomab, Stenoparib, DP-303c, and others
*
Advanced Ovarian Cancer Therapeutic Assessment: Advanced Ovarian Cancer current marketed and Advanced Ovarian Cancer emerging therapies
*
Advanced Ovarian Cancer Market Dynamics: Advanced Ovarian Cancer market drivers and Advanced Ovarian Cancer market barriers
Request for Sample PDF Report for Advanced Ovarian Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Advanced Ovarian Cancer Report Introduction
2. Advanced Ovarian Cancer Executive Summary
3. Advanced Ovarian Cancer Overview
4. Advanced Ovarian Cancer- Analytical Perspective In-depth Commercial Assessment
5. Advanced Ovarian Cancer Pipeline Therapeutics
6. Advanced Ovarian Cancer Late Stage Products (Phase II/III)
7. Advanced Ovarian Cancer Mid Stage Products (Phase II)
8. Advanced Ovarian Cancer Early Stage Products (Phase I)
9. Advanced Ovarian Cancer Preclinical Stage Products
10. Advanced Ovarian Cancer Therapeutics Assessment
11. Advanced Ovarian Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Advanced Ovarian Cancer Key Companies
14. Advanced Ovarian Cancer Key Products
15. Advanced Ovarian Cancer Unmet Needs
16 . Advanced Ovarian Cancer Market Drivers and Barriers
17. Advanced Ovarian Cancer Future Perspectives and Conclusion
18. Advanced Ovarian Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-ovarian-cancer-pipeline-2025-indepth-clinical-trials-analysis-and-emerging-therapies-report-by-delveinsight-pfizer-daiichi-sankyo-astellas-pharma-jiangsu-hengrui-boehringer-ingelheim]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Ovarian Cancer Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim here
News-ID: 4202502 • Views: …
More Releases from ABNewswire
Renew & Restore Exterior Cleaning, LLC Elevates Standards for Power Washing Serv …
Homeowners and businesses alike understand the importance of maintaining a clean, welcoming property. Dirt, mildew, algae, and grime not only impact curb appeal but can also damage exterior surfaces over time. That's why Renew & Restore Exterior Cleaning, LLC has expanded its professional cleaning solutions to provide the most trusted power washing service in Melbourne and surrounding areas. With a focus on quality, safety, and long-lasting results, the company continues…
HER2-Positive Breast Cancer Pipeline 2025: Therapies Under Investigation, Clinic …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, HER2-Positive Breast Cancer pipeline constitutes 50+ key companies continuously working towards developing 55+ HER2-Positive Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"HER2-Positive Breast Cancer Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HER2-Positive Breast Cancer Market.
The…
SoulfulTravelGuy.com Provides Human Reviews as AI Content Dominates Travel Indus …
As the travel content landscape becomes increasingly dominated by artificial intelligence reviews, soulfultravelguy.com [https://soulfultravelguy.com/] has positioned itself as a trusted source for authentic premium travel experiences. The independent travel blog has comprehensive, personally-experienced reviews of Delta One seats [https://soulfultravelguy.com/article/delta-international-first-class], British Airways business class seats, and Virgin Atlantic Upper Class [https://soulfultravelguy.com/article/virgin-atlantic-upper-class-review-herringbone] products that cannot be replicated by AI-generated content.
Soulful Travel Guy has developed particular expertise in airport lounges, with detailed coverage…
Four Stocks Shaping the Future of Finance (ATHR,FDS,TRI,NDAQ)
The financial information economy has quietly become one of the most durable growth stories in markets. Industry revenues climbed from $33 billion in 2019 to $42 billion in 2024 and are projected to grow 7% annually through 2030, according to Burton-Taylor International Consulting.
The financial information economy has quietly become one of the most durable growth stories in markets. Industry revenues climbed from $33 billion in 2019 to $42 billion in…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
